Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf167 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Oncologist, 2025. Verfasst von Kunihiro Odagiri und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cachexia. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nitto Foundation, CASIO SCIENCE PROMOTION FOUNDATION, Foundation for Promotion of Cancer Research.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Cancer cachexia reduces chemotherapy efficacy in patients with metastatic urothelial carcinoma (mUC). Anamorelin improves cancer cachexia by increasing serum insulin-like growth factor 1 (IGF-1). The aim of this study was to evaluate the efficacy and safety of anamorelin in patients with mUC.
Methods
A total of 38 patients with mUC who received platinum-based chemotherapy were enrolled in an interventional prospective study. Patients were randomized to anamorelin (Ana; n = 20) or control (n = 18) groups. The primary endpoint was the change in prealbumin. Secondary endpoints were changes in albumin, IGF-1, body weight, skeletal muscle mass index (SMI), interleukin-6 (IL-6) and median overall survival (mOS).
Results
Changes in prealbumin, albumin, body weight, and SMI were similar between groups. Compared to control, serum IGF-1 levels in the anamorelin-treated group were higher after 1 week (P < .05). Changes in IGF-1 and SMI positively correlated in the anamorelin group (R = 0.61, P < .05). When the anamorelin group was divided into 2 groups by the median serum IGF-1 level after 1 week (Ana-IGF-1 high and Ana-IGF-1 low groups), the SMI in the latter group showed a decreased tendency (P = .14). The Ana-IGF-1 low group showed significantly higher IL-6 levels (P < .05) at baseline and significantly shorter mOS compared to the Ana-IGF-1 high group (P < .05). Treatment-related adverse events were comparable between the 2 groups (any grade: 100% vs 100%; grade ≥3: 88.9% vs 90.0%).
Conclusions
Anamorelin was well tolerated in patients with mUC. A higher serum IGF-1 level might be associated with anamorelin efficacy; however, a larger study is needed to confirm this.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Urology, Nagoya City University West Medical Center, Nagoya, Japan.
- Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
ORCID-Profile: Taku Naiki, Aya Naiki-Ito
Förderung
- Nitto Foundation
- CASIO SCIENCE PROMOTION FOUNDATION
- Foundation for Promotion of Cancer Research
- KAKENHI
Zitieren
APA
Odagiri, K., Mimura, Y., Naiki, T., Tasaki, Y., Sugiyama, Y., Naiki-Ito, A., Etani, T., Nagai, T., Morikawa, T., Shimizu, N., Aoki, M., Gonda, M., Yasui, T., & Furukawa-Hibi, Y. (2025). Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study. The Oncologist. https://doi.org/10.1093/oncolo/oyaf167
Vancouver
Odagiri K, Mimura Y, Naiki T, Tasaki Y, Sugiyama Y, Naiki-Ito A, et al. Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study. The Oncologist. 2025. doi:10.1093/oncolo/oyaf167
BibTeX
@article{Odagiri2025,
author = {Odagiri, Kunihiro and Mimura, Yoshihisa and Naiki, Taku and Tasaki, Yoshihiko and Sugiyama, Yosuke and Naiki-Ito, Aya and Etani, Toshiki and Nagai, Takashi and Morikawa, Toshiharu and Shimizu, Nobuhiko and Aoki, Maria and Gonda, Masakazu and Yasui, Takahiro and Furukawa-Hibi, Yoko},
title = {Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf167}
}
EUVIMED